Navigation Links
Crohn's Disease Drug Market and Pipeline Analysis: 2014 Report
Date:10/8/2014

DUBLIN, Oct. 8, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Crohn's Disease Drug Market and Pipeline Analysis" report to their offering.

Under the umbrella of inflammatory bowel diseases, Crohn's disease and ulcerative colitis are two most common disorders. Though both these disorders have similar symptoms, the difference arises in the areas affected in the gastrointestinal tract (GI tract). The Crohn's disease in most cases affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the gastrointestinal (GI) tract, from the mouth to the anus.

On the other hand, ulcerative colitis affects only the colon, which is also called the large intestine. Additionally, there is also the possibility of Crohn's disease affecting the entire thickness of the bowel wall, while ulcerative colitis only impacts the innermost lining of the colon. Also, in Crohn's disease, the inflammation of the intestine can miss some normal areas in between patches of diseased intestine, which does not occur in ulcerative colitis. It has been observed that though age is no basis for this disease, Crohn's is more prevalent among adolescents and young adults between the ages of 15 and 35.

Pharmaceutical companies have been increasingly attracted towards developing many new drug compounds for Crohn's disease owing to the size of the market and the limitations of current treatments. There is a variety of therapies, both current and future, which are based on different mechanisms of action including TNF-alpha inhibitors, IL-12 and 23 inhibitors, IL-6 inhibitors, IL-17 inhibitors, chemokine receptor inhibitors, co-stimulation modulators, anti-CD3 molecules, anti-MAP agents, cell adhesion molecule inhibitors, oral adsorbents, other immunosupressants, and stem cell therapy.

There is significant room for future discovery in the market for Crohn's disease drugs. As the exact causes are still unknown, the appropriate cure is yet to be developed. However, there are new studies which are under way, and the medications which have been recently introduced in the market are proving to be efficient to a certain extent.

It is expected that the future of Crohn's disease market would witness significant improvements in the diagnostic techniques as the researchers would get a deeper understanding of the disease. Thus, overall, there is significant amount of research currently underway for developing newer and innovative drug compounds to treat patients with Crohn's disease. With the launch of the new compounds in the next 3-5 years, it is most likely that this market would offer better solutions for the patients.

Crohn's Disease Drug Market and Pipeline Analysis Report Highlight

  • Crohn's Disease Market Overview
  • Crohn's Disease Clinical Trial Insight by Phase & Country
  • Competitive Landscape
  • Crohn's Disease Drug Clinical Development Phase
  • Majority Drugs in Phase-II Development
  • Marketed Drugs
  • Suspended & Discontinued Drugs

Key Topics Covered:

1. Crohn's Disease Market Overview

2. EMA Guidelines on Development Crohn's Disease Drug

3. Crohn's Disease Clinical Trial Insight by Phase & Country

4. Marketed Crohn's Disease Drugs: Clinical Profile & Patent Insight

5. Suspended & Discontinued Profiles by Clinical Phase & County

6. Competitive Landscape

Companies Mentioned:

  • Amgen
  • Boehringer Ingelheim
  • Cambridge Antibody Technology (MedImmune)
  • Centocor (Janssen Biotech)
  • Pfizer
  • Tillotts Pharma (Zeria Pharmaceutical)

For more information visit http://www.researchandmarkets.com/research/45b94n/crohns_disease

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
3. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
4. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
5. Chef Spike Mendelsohn Dishes on How to Turn Down the Heat on Acid Reflux Disease
6. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
7. The ALS Therapy Development Institute Partners with Neurotune to Investigate Potential Treatments for Motor Neuron Disease
8. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
9. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
10. UCB Proudly Reinforces Long-Standing Commitment to Crohns Disease Community at Digestive Disease Week 2012
11. Receptos to Deliver Scientific Presentation at Digestive Disease Week 2012 about the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):